Amphetamine effects on dopamine release and synthesis rate studied in the Rhesus monkey brain by positron emission tomography

Journal of Neural Transmission

Volumn 104, Issue 4-5, 1997, Pages 329-339

  Hartvig, P ^a,b,c   Torstenson, R ^a   Tedroff, J ^a,b   Watanabe, Y ^a,c   Fasth, K J ^a,c   Bjurling, P ^a,c   Langstrom B ^a,c  

^a UPPSALA UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^c JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

Author keywords

11C ; Amphetamine; CBF; L DOPA; Monkeys; N methylspiperone; PET; Raclopride

Indexed keywords

3 METHYLSPIPERONE; AMPHETAMINE; DEXAMPHETAMINE; DOPA; DOPAMINE; DOPAMINE RECEPTOR; DOPAMINE RECEPTOR BLOCKING AGENT; PRESYNAPTIC RECEPTOR; PROPOFOL; RACLOPRIDE;

ANIMAL EXPERIMENT; ARTICLE; BINDING SITE; CONTROLLED STUDY; DOPAMINE METABOLISM; DOPAMINE RELEASE; DOPAMINERGIC SYSTEM; DRUG BLOOD LEVEL; FEMALE; ISOTOPE LABELING; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RECEPTOR BINDING; RHESUS MONKEY;

AMPHETAMINE; ANIMALS; BRAIN; CEREBROVASCULAR CIRCULATION; DECARBOXYLATION; DOPAMINE; DOPAMINE AGENTS; DOPAMINE AGONISTS; DOPAMINE ANTAGONISTS; FEMALE; LEVODOPA; MACACA MULATTA; RACLOPRIDE; SALICYLAMIDES; SPIPERONE; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0030864430     PISSN: 03009564     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF01277655     Document Type: Article

References (36)

1. Andersson JLR (1995) A rapid and accurate method to realign PET scans utilizing image edge information. J Nucl Med 36: 657-669
2. Argiolas A, Fadda F, Stefani E, Gessa GL (1978) Evidence for a direct action of amphetamine on dopamine metabolism in the rat substantia nigra in vivo. Naunyn Schmiedebergs Arch Pharmacol 301: 171-174
3. Bjurling P, Watanabe Y, Oka S, Nagasawa T, Yamada H, Långström B (1990) Multienzymatic synthesis of 11C-labelled L-tyrosine and L-dopa. Acta Chem Scand 44: 178-182
4. Brooks D, Ibanez V, Sawle GV (1992) Striatal D2 receptor status in patients with Parkinson's disease, striatonigral degeneration and progressive supranuclear palsy, measured with 11C-raclopride and positron emission tomography. Ann Neurol 31: 184-192
5. 3H]dopamine binding associated with dopamine receptors in calf brain membranes. Mol Pharmacol 12: 800-812
6. Butcher SP, Fairbrother IS, Kelly JS, Arbuthnott GW (1988) Amphetamine-induced dopamine release in the rat striatum: an in vivo microdialys study. J Neurochem 50: 346-355
7. Carson RE, Huang SC, Green MV (1986) Weighted integration method for local cerebral blood flow measurements with positron emission tomography. J Cereb Blood Flow Metab 6: 245-258
8. 18F)-N-methylspiperidol binding in the baboon brain using positron emission tomography. Synapse 7: 324-327
9. 11C-raclopride is altered by drugs that modify synaptic dopamine levels. Synapse 13: 350-356
10. Dexamphetamine (1991) In: Dollery C et al. (eds) Therapeutic drugs, vol 1. Churchill Livingstone, Edinburgh, pp D50-D55
11. Edling C, Hellman B, Arvidsson B, Lilja A, Andersson J, Hartvig P, Valind S, Långström B (1997) Positron emission tomography studies of subjects occupationally exposed organic solvents. Evidence of increased dopamine synthesis rate. Int Arch Occup Environ Health (in press)
12. Eriksson L, Holte S, Bohm C, Kesselberg M, Hovander B (1988) Automated blood sampling systems for positron emission tomography. IEEE Trans Nucl Sci 35: 703-704
13. Giros B, Jaber M, Jones SR, Wightmann RM, Caron MG (1996) Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature 379: 606-612
14. 11C]DOPA in humans studied by positron emission tomography. J Neural Transm [GenSect] 86: 25-41
15. 15O. I. Theory and error analysis. J Nucl Med 24: 782-789
16. 123I]IBZM binding to the D2 receptor in nonhuman primates. Synapse 10: 177-184
17. Kamata K, Rebec GV (1984) Long-term amphetamine treatment attenuates or reverses the depression of neuronal activity produced by dopamine agonists in the ventral tegmental area. Life Sci 34: 2419-2427
18. Kuzcenski R, Segal D (1989) Concomitant characterization of behavioral and striatal neurotransmittor response to amphetamine using in vivo microdialysis. J Neurosci 9: 2051-2086
19. Laruelle M, Iyer RN, Al-Tikritit MS, Zea-Ponce Y, Malison R, Zoghbi SS, Baldwin RM, Kung HF, Charney DS, Hoffer PB, Innis RB, Bradberry CW (1997) Microdialysis and SPECT measurements of amphetamine-induced dopamine release in nonhuman primates. Synapse 25: 1-14
20. Leshner AI (1996) Molecular mechanism of cocaine addiction. N Engl J Med 335: 128-129
21. 11C]DOPA and its metabolites for the validation of positron emission tomographic studies. J Pharm Biomed Anal 13(4-5): 361-367
22. Logan J, Volkow ND, Fowler JS, Wang GJ, Dewey SL, Schlyer DJ, MacGregor RR (1993) The effects of change in blood flow on the distribution volume of (11C)raclopride binding. J Nucl Med 34: 200P
23. 11C)methionine. J Nucl Med 28: 1037-1040
24. McMillen B (1983) CNS stimulants: two distinct mechanisms of action of amphetamine like drugs. Trends Pharmacol Sci Oct: 429-432
25. 15O autoradiographical method and dynamic PET. J Nucl Med 30: 1069-1078
26. Miller HH, Shore P (1982) Effects of amphetamine and amfonelic acid on the disposition of striatal newly synthetized dopamine. Eur J Pharmacol 78: 33-44
27. 15O. II. Implementation and validation. J Nucl Med 24: 790-798
28. 3H]raclopride: implications for positron tomography of the human brain. Synapse 3: 96-96
29. Seutin V, Verbanck P, Massotte L, Dresse A (1991) Acute amphetamine induced subsensitivity of A10 dopamine autoreceptors in vivo. Brain Res 558: 141-144
30. Tedroff J, Aquilonius SM, Hartvig P, Bjurling P, Långström B (1992) Estimation of regional cerebral utilization of [11C]-1-3,4-dihydroxyphenylalanine (DOPA) in the primate by positron emission tomography. Acta Neurol Scand 85: 215-225
31. 11C]raclopride displacement and PET. Neurology 46: 1430-1436
32. Tedroff J, Torstenson R, Hartvig P, Lindner KJ, Watanabe Y, Bjurling P, Westerberg G, Långström B (1997) L-DOPA modulates striatal dopaminergic function in vivo: evidence from PET investigations in nonhuman primates. Synapse 25: 56-61
33. Torstenson R, Hartvig P, Långström B, Tedroff J (1997) Differential effect of levodopa infusion in early and advanced Parkinson's disease. Ann Neurol (in press)
34. White FJ, Wang RY (1984) Electrophysiological evidence for A10 dopamine autoreceptor subsensitivity following chronic D-amphetamine treatment. Brain Res 309: 283-292
35. Young LT, Wong DF, Goldman S, Minkin E, Chen C, Matsumura K, Scheffel U, Wagner HN Jr (1991) Effects of endogenous dopamine kinetics of [3H]N-methylspiperone and [3H]raclopride binding in the rat brain. Synapse 9: 188-194
36. Zetterström T, Sharp T, Marsden CA, Ungerstedt U (1983) In vivo measurement of dopamine and its metabolites by intracerebral dialysis: changes after D-amphetamine. J Neurochem 41: 1769-1773